MedPath

Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma

Phase 4
Conditions
Bronchial asthma
Registration Number
JPRN-UMIN000002389
Lead Sponsor
Kyoto University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with hypersensitiviry to omalizumab 2)Patients with obstructive lung diseases such as chronic bronchitis or COPD, or bronchiectasis 3)Pregnancy or lactation 4)Patients with non-atopic diseases associated with elevated serum total IgE levels 5)Patients who are considered inappropriate by physicians in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath